Use of ciclesonide for the treatment of respiratory diseases

Abstract

Disclosed herein are novel methods of treating respiratory diseases, and in particular the treatment of asthmatic children.

1 . A method for treating or preventing a respiratory disease in a child comprising administering to the child a dose of a composition comprising ciclesonide, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, wherein the dose of the composition comprises ciclesonide in an amount of from 20 to 200 μg. 
     
     
         2 - 10 . (canceled) 
     
     
         11 . The method according to  claim 1  wherein ciclesonide is selected from the group consisting of [11β,16α(R)]--16,17-[(Cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-dien-3,20-dion, [11β,16α(S)]-16,17-[(Cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-dien-3,20-dion, [11β,16α(R,S)]-16,17-[(Cyclohexyl-methylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxoprop-oxy)pregna-1,4-dien-3,20-dion, 16α,17-(22R)-Cyclohexylmethylendioxy-11β,21-dihydroxypregna-1,4-dien-3,20-dion, 16α,17-(22S)-Cyclohexylmethylendioxy-11β,21-dihydroxypregna-1,4-dien-3,20-dion and 16α,17-(22R,S)-Cyclohexylmethylendioxy-11β,21-dihydroxy-pregna-1,4-dien-3,20-dion. 
     
     
         12 - 42 . (canceled)